ClinicalTrials.gg
RecruitingNCT06747923Updated Nov 19, 2025

SB17170 Phase 2 Trial in IPF Patients

A Phase 2 interventional study of SB17170 and Placebo in IPF, Idiopathic Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis (IPF), sponsored by SPARK Biopharma. Recruiting at 5 sites in South Korea. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by SPARK Biopharma · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Idiopathic Pulmonary Fibrosis with a site in Korea, Republic of — 12 open to participants now, 19 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Korea, Republic of.

Planned enrollment
45th of 47
30 · median 240
Started
2025
with 3 others
Phase 2
26 of 53
6 open now
Primary completion
2026-05
later than 3 of 18 live
Registered
43rd of 53
by date

Among the 53 studies in Idiopathic Pulmonary Fibrosis with a site in Korea, Republic of, this one is the 45th largest by planned enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2025, is one of 26 in phase 2, reaches primary completion later than 3 of the 18 other live ones, and was the 43rd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

12 of the 53 studies in Idiopathic Pulmonary Fibrosis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Idiopathic Pulmonary Fibrosis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.

Read the detailed description

Idiopathic pulmonary fibrosis (IPF) is a progressive respiratory disease characterized by a scarring process of the lung, bringing patients to respiratory failure and death in 3-5 years from diagnosis.

Subjects who meet the inclusion/exclusion criteria as a result of the screening test shall be randomized into Test Group 1 (SB17170 A mg), Test Group 2 (SB17170 B mg) and Control Group (Placebo for SB17170) in 2:2:1. Subjects who have been randomized will orally take 2 capsules once daily after a meal according to their assigned administration group for 12 weeks from the date they are prescribed the investigational product.

Safety and tolerability at 12 weeks after randomization, and efficacy at 4 \& 12 weeks will be assessed. The subject who has completed 12 weeks of treatment shall visit the trial site after 1 week (Visit 7, EOS) for a follow-up.

03

Conditions studied

  • IPF
  • Idiopathic Pulmonary Fibrosis
  • Idiopathic Pulmonary Fibrosis (IPF)

Keywords

  • HMGB1
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male/female 40 years or older at the time of obtaining
  2. Patients diagnosed with idiopathic pulmonary fibrosis who meet the following criteria:

    • Patients with idiopathic pulmonary fibrosis who are confirmed by chest High-Resolution Computed Tomography (HRCT) scan
    • Patients with Usual Interstitial Pneumonia (UIP) or probable UIP HRCT pattern consistent with a diagnosis of idiopathic pulmonary fibrosis confirmed through central reading of chest HRCT before the baseline visit
  3. Patients with a history of idiopathic pulmonary fibrosis treatment who meet the defined criteria
  4. Patients with Forced Vital Capacity (FVC) ≥ 45% of the normal predicted value at the screening visit
  5. Patients meeting pulmonary function test criteria at the screening visit
  6. Patients who have received the explanation of this clinical trial and voluntarily agreed and signed the informed consent form

Exclusion criteria

Exclusion Criteria:

  1. When there is a primary disease showing UIP patterns (rheumatoid arthritis-related interstitial lung disease, connective tissue disease-related interstitial lung disease, etc.) and/or other lung abnormalities
  2. Patients with confirmed acute exacerbation of IPF within 6 months prior to screening and/or during the screening period
  3. Patients with lower respiratory tract infections requiring antibiotic treatment
  4. Patients who underwent major surgery within 3 months before screening or have major surgery planned during the clinical trial
  5. Patients with a history of or documented evidence of active or suspected malignancy within 5 years prior to screening
  6. Patients with evidence of active infection
  7. Patients with the following cardiovascular and cerebrovascular diseases at the time of screening:

    • Severe hypertension within 3 months
    • Myocardial infarction or unstable angina within 6 months
    • History of thrombotic events within 6 months
    • Diagnosis of heart failure within 6 months
  8. Patients with pulmonary hypertension
  9. Patients who are unable to take drugs orally or have a history of major gastrointestinal surgery or pathological findings that may affect the absorption of the product
  10. Patients with (HIV) infection or active or C
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    SB17170 of A mg, Single dose

    Drug: SB17170

  • Experimental
    SB17170 of B mg, Single dose

    Drug: SB17170

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Taking SB17170 orally once a day

  • DrugPlacebo

    Taking Placebo orally once a day

06

What researchers measure

Primary outcomes

  1. Change from baseline in FVC (ml)

    Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.

    Time frame: Week 12

Secondary outcomes

  1. Change from baseline in FVC (%)

    Change from baseline in FVC (%) compared to normal predicted values at 12 weeks

    Time frame: Week 12

  2. Change from baseline in DLCO

    DLCO was a measurement to determine the extent to which oxygen passes from the air sacs of the lungs into the blood.

    Time frame: Week 12

  3. Change from baseline in quality of life and symptoms

    Living with Pulmonary Fibrosis (L-PF) questionnaire : Scores range from 0 to 100, with higher numbers indicating a greater impairment.

    Time frame: Week 12

  4. Change from baseline in quality of life and symptoms

    EuroQoL Five-Dimensional Instrument(EQ-5D) : Scores range from -0.594 to 1.0, with higher numbers indicating a better health

    Time frame: Week 12

  5. Change from baseline in quality of life and symptoms

    UCSD Shortness of Breath Questionnaire : Scores range from 0 to 120, with higher numbers indicating greater shortness of breath.

    Time frame: Week 12

07

Study locations

2 of 5 sites recruiting
  • Myong Ji Hospital
    Goyang, South Korea
    Recruiting
    • Wonil Choi, M.D. · Contact
  • Chung-Ang University Gwangmyeong Hospital
    Gwangmyeong, South Korea
    Recruiting
    • Jin Young Huh · Contact
  • Seoul Asan Hospital
    Seoul, South Korea
    Not yet recruiting
    • Jin Woo Song, M.D. · Contact
  • The Catholic Univ. of Korea Seoul St. Mary's Hospital
    Seoul, South Korea
    Not yet recruiting
    • Yong Suk Jo, M.D. · Contact
  • Ajou University Hospital
    Suwon, South Korea
    Not yet recruiting
    • Joo Hun Park, M.D. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for May 2026, 16 months after the start.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 16 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 24, 2024
StartActual
Jan 27, 2025
Primary completionEst.
May 30, 2026
CompletionEst.
Oct 31, 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06747923
Lead sponsor
SPARK Biopharma
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Jan 27, 2025
Primary completion
May 30, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

Seong Yun Bang
Contact
sybang@sparkbio.co.kr
+82-2-887-8032
Yu Jin Choi
Contact
yjchoi@sparkbio.co.kr
+82-2-887-9972

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HMGB1 Inhibitor SB17170

Start the discussion